David Hart Appointed New CEO of the Bermuda Business Development Agency (BDA)
7.9.2021 18:57:00 EEST | Business Wire | Press release
The Bermuda Business Development Agency (BDA) announced today that Mr. David Hart has been appointed as the new Chief Executive Officer (CEO) of the BDA effective 1 October 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210907005694/en/
David Hart, new BDA CEO (Photo: Business Wire)
Prior to joining the BDA, Mr. Hart served as Executive Vice President of the Florida Chamber of Commerce, one of the largest and most successful business advocacy organisations in the United States, where he was part of the leadership team responsible for consistently enhancing the environment to increase job growth, diversify the economy and attract additional capital investments. Through collaborations with public and private sector partners these efforts contributed to Florida creating one of every 11 jobs in the United States, attracting $1.19 million in capital every hour, and recently becoming ranked as the 15th largest economy in the world.
Mr. Hart said, “I am very excited and honoured to be joining the BDA team. The BDA’s mission of fostering sustainable, equitable prosperity for Bermuda, and encouraging jobs, investment, and innovation to come to the Island, has never been more important. I am thrilled to join a world class team and accelerate our efforts to bring investment and jobs to Bermuda. Bermuda’s track record of leadership on a global scale, access to world markets and talented pool of human capital are significant strengths as we seek to diversify Bermuda’s economy and support our trading partners worldwide.”
Stephen Weinstein, BDA Chair said, “On behalf of the Board of Directors, we welcome Mr. Hart to the BDA and the Bermuda community at this critical time. His leadership, communication skills, and deep experience in economic development and public policy, are perfect fits for our next stage of challenges and growth.”
“We thank Roland Andy Burrows for nearly three years of dedicated service as CEO,” Mr. Weinstein said. “Under his leadership, the BDA helped navigate Bermuda through one of its most trying economic periods and we wish him well in his future endeavours.”
Mr. Burrows will continue to support the agency as a senior consultant through year-end to support the leadership transition.
Mr. Burrows said, "The BDA plays a vital role in promoting Bermuda. I am proud of what the BDA has achieved since December 2018 and will continue to support its mission.”
Mr. Hart’s new appointment highlights the Board’s and the BDA’s continued commitment to international business development. With an aim to increase international investment through innovation, strategic partnerships and targeted marketing of Bermuda’s world class business platform, the BDA has also created a new Business Development Committee chaired by BDA board member George Thomas. Mrs. Susan Pateras, BDA Deputy Chair, has been appointed Interim CEO and will oversee operations until Mr. Hart commences service. Mr. Hart’s service in Bermuda is subject to Bermuda Immigration approval.
CONNECTING BUSINESS
The BDA encourages direct investment and helps companies start up, re-locate or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Our goal? To make doing business in Bermuda smooth and beneficial.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005694/en/
Contact information
Stuart Roberts, Director of Communications & PR
stuart@bda.bm
+1 441 707 0038
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
